Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple CO2 test save lives in septic shock?

NCT ID NCT07179276

Knowledge-focused Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two methods for guiding early treatment in people with septic shock, a severe infection that can cause organ failure. The standard approach uses blood lactate levels, but this trial tests whether using the CO2 gap (a measure of blood flow) is better at reducing deaths. About 750 adults in intensive care will take part, and the main goal is to see if more people survive at 28 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 750 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older AND * Acutely admitted to a study ICU AND * Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as: * A suspected or documented site of infection or positive blood culture AND * Acute increase of at least 2 points in the Sequential Organ Failure Assessment (SOFA) score consequent to the infection AND * Having a serum lactate level \>2 mmol/l AND * Requirement of vasopressors (any dose of norepinephrine) to maintain mean arterial pressure (MAP) ≥65 mmHg despite adequate fluid resuscitation (at least 1L of IV fluid in the last 24 hours prior to screening) Exclusion Criteria: * Septic shock for more than 12 hours at the time of screening * Primary cause of hypotension not due to sepsis (e.g., acute bleeding) * Decision not to resuscitate (or to limit full care) or not to intubate taken before obtaining consent * Death is deemed to be imminent or inevitable or patients with an underlying disease process with a life expectancy of less than 3 months * Anticipated surgery during the first 24 hours after randomization * Patient or their relatives' refusal to participate * Patients participating in another RCT with interventions possibly compromising the primary outcome * Prior enrollment in the CARBON trial * Known to be pregnant. * Legal protection (i.e., incompetence to provide consent and no guardian or incarceration) * No affiliation with the French health care system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis - to reduce mortality in the intensive care unit are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis - to reduce mortality in the intensive care unit Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    28 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP HM Hôpital la Timone

    RECRUITING

    Marseille, France

  • APHP Beaujon

    RECRUITING

    Paris, France

  • APHP Bicêtre

    RECRUITING

    Paris, France

  • APHP La pitié Salpêtrière - Anesthésie et soin intensif

    RECRUITING

    Paris, France

  • APHP Lariboisière

    RECRUITING

    Paris, France

  • CH Aurillac

    NOT_YET_RECRUITING

    Aurillac, France

  • CH Le puy en Velay

    RECRUITING

    Le Puy-en-Velay, France

  • CH Moulins-Yzeure

    NOT_YET_RECRUITING

    Moulins, France

  • CH Vichy

    NOT_YET_RECRUITING

    Vichy, France

  • CH de la Côte Basque

    RECRUITING

    Bayonne, France

  • CHRU Strasbourg - Service d'anesthésie-Réanimation médicale

    RECRUITING

    Strasbourg, France

  • CHU Bordeaux Hôpital Haut Lévèque

    RECRUITING

    Bordeaux, France

  • CHU Bordeaux Pellegrin Hospital

    RECRUITING

    Bordeaux, France

  • CHU Clermont-Ferrand Estaing

    RECRUITING

    Clermont-Ferrand, France

  • CHU Clermont-Ferrand Gabriel Montpied

    RECRUITING

    Clermont-Ferrand, France

  • CHU Dijon

    RECRUITING

    Dijon, France

  • CHU Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • CHU Montpellier

    RECRUITING

    Montpellier, France

  • CHU Nantes

    RECRUITING

    Nantes, France

  • CHU Nîmes

    NOT_YET_RECRUITING

    Nîmes, France

  • CHU Poitiers

    RECRUITING

    Poitiers, France

  • CHU Rennes

    RECRUITING

    Rennes, France

  • CHU Strasbourg Service d'Anesthésie-Réanimation chirurgicale

    RECRUITING

    Strasbourg, France

  • CHU la pitié slapêtrière - Anesthésie Réanimation

    RECRUITING

    Paris, France

  • CHu Angers

    NOT_YET_RECRUITING

    Angers, France

  • Chu Toulouse

    RECRUITING

    Toulouse, France

  • HCL - Lyon Sud

    NOT_YET_RECRUITING

    Lyon, France

  • HCL Hôpital Edouard Herriot

    NOT_YET_RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.